ATAI — AtaiBeckley Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 2081043 ·
Last close
$4.29
Market Cap
$1.58B
52W High
$5.51
52W Low
$3.27
ADV30
6,757,341
Next earnings
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. The company was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 954,000 -30,159,000 -29,782,000 264,877,000 43,102,000 66,098,000
Dec 2025 1,066,000 -39,353,000 -544,813,000 292,723,000 85,300,000 70,722,000
Sep 2025 749,000 -28,407,000 -61,074,000 239,820,000 30,402,000 79,912,000
Jun 2025 719,000 -25,245,000 -27,729,000 189,204,000 61,940,000 45,279,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-102,675,000
Investing CF
$-109,127,000
Financing CF
$269,481,000
CapEx
$-10,868,000
Dividends Paid
Buybacks
$-4,468,000
EPS Diluted TTM
$-2.30
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,360,254,000
Inventory
Receivables
$14,427,000
ST Investments
$170,740,000
EBIT TTM
$-658,687,000
Pretax Income TTM
$-659,849,000
Interest Exp TTM
$1,162,000
Analysts
12

Yahoo Snapshot (yfinance, live)

Total Revenue
$3,488,000
EBITDA
$-120,710,000
Free Cash Flow
Enterprise Value
$1,315,389,952
Total Cash
$230,767,008
Total Debt
$2,000,000
Shares Out
368,166,674
Trailing EPS
$-2.84
Book Value
$0.56
ROE
-378.0%
ROA
-33.0%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 4,089,000 -113,347,000 -660,047,000 292,723,000 70,722,000 -102,675,000
Dec 2024 308,000 -102,166,000 -149,269,000 159,387,000 42,833,000 -82,437,000
Dec 2023 314,000 -123,026,000 -40,224,000 293,478,000 49,162,000 -84,118,000
Dec 2022 233,000 -144,430,000 -152,385,000 305,441,000 39,675,000 -104,467,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.46

Peers — same industry

TickerNameMarket CapLastDaily %
QURE uniQure N.V. $1.59B $25.15
GHRS GH Research PLC $1.59B $23.15
DMRA Damora Therapeutics, Inc. $1.59B $25.89
ABCL AbCellera Biologics Inc. $1.62B $5.29
ARDX ARDELYX, INC. $1.54B $6.25

News headlines (Yahoo Finance, 1h cache)

AtaiBeckley (ATAI) Reports Q1 Financial Results
2026-05-22 18:43 · Yahoo
A Look At AtaiBeckley (ATAI) Valuation As Share Price Momentum And DCF Signal Differ
2026-05-16 00:22 · Yahoo
AtaiBeckley clinical pipeline advances toward multiple late-stage data catalysts, Jefferies says
2026-05-13 17:06 · Yahoo
AtaiBeckley targets Q2 start for Phase 3 depression trial as pipeline advances
2026-05-12 13:22 · Yahoo
AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update
2026-05-12 12:00 · Yahoo
AtaiBeckley (ATAI) Reports Positive Phase 2a Results for Social Anxiety Treatment EMP-01
2026-05-10 04:00 · Yahoo
Does AtaiBeckley’s (ATAI) EMP-01 Data Hint At A Scalable MDMA Therapy Platform?
2026-05-01 15:19 · Yahoo
These 3 Psychedelic Stocks Activated After Trump's Executive Order
2026-04-27 15:15 · Yahoo
AtaiBeckley wins OVID Health Silver Award for patient partnership in psychedelic trials
2026-04-27 12:22 · Yahoo
AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research
2026-04-27 08:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.